Literature DB >> 28579014

Executive summary of the consensus document on osteoporosis in HIV-infected individuals.

Eugenia Negredo1, Pere Domingo2, Félix Gutiérrez3, María José Galindo4, Hernando Knobel5, Fernando Lozano6, Esteban Martínez7, Mar Masiá3, Rosa Polo8, Vicente Estrada9.   

Abstract

Osteoporosis has become an emerging comorbid condition in people living with HIV (PLWH). The increase in survival and the progressive aging of PLWH will make this complication more frequent in the near future. In addition to the traditional risk factors affecting the general population, factors directly or indirectly associated with HIV infection, including antiretroviral therapy, can increase the risk of osteoporosis. The present article is an executive summary of the document that updates the previous recommendations on the prevention and treatment of osteoporosis in PLWH. This document is intended for all professionals who work in clinical practice in the field of HIV infection.
Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; HIV infection; Infección por el VIH; Osteoporosis; Tratamiento antirretroviral

Mesh:

Year:  2017        PMID: 28579014     DOI: 10.1016/j.eimc.2017.03.010

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin (Engl Ed)        ISSN: 2529-993X


  2 in total

1.  High Prevalence of Sarcopenia in HIV-Infected Individuals.

Authors:  Patricia Echeverría; Anna Bonjoch; Jordi Puig; Carla Estany; Arelly Ornelas; Bonaventura Clotet; Eugenia Negredo
Journal:  Biomed Res Int       Date:  2018-07-12       Impact factor: 3.411

2.  Increased risk factors associated with lower BMD in antiretroviral-therapy-naïve HIV-infected adult male.

Authors:  Patricia Atencio; Alfonso Cabello; Aránzazu Mediero; Miguel Górgolas; Francisco M Conesa-Buendía; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Irene Carrillo; Beatriz Álvarez; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Gabriel Herrero-Beaumont
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.